Table 1. Characteristics of 6 patients... | American Society of Hematology

Table 1.

Characteristics of 6 patients with inhibitors against FVIII treated with 2-chlorodeoxyadenosine

Pt	Age/Sex	Underlying condition	Titer at treatment, BU/mL		Bleeding	Time to 50% increase in FVIII, d	Time to 50% decline in inhibitor, d	Time to nadir inhibitor, d	Nadir inhibitor titer (BU/mL)		Maximum FVIII, %
Pt	Age/Sex	Underlying condition	Human	Porcine	Bleeding	Time to 50% increase in FVIII, d	Time to 50% decline in inhibitor, d	Time to nadir inhibitor, d	Human	Porcine	Maximum FVIII, %
1	72/M	Chronic lymphocytic leukemia	26	3	Soft tissues	95	68	117	3	0	62
2	63/M	None	162	16	Soft tissues, hematuria	265	124	280	2	1	54
3	67/F	Scleroderma	24	2	Postoperative	105	79	145	2	1	82
4	59/F	Systemic lupus erythematosus	36	8	Skin, hemarthrosis	128	84	129	4	2	87
5	78/M	Colon cancer resected 2 years prior to inhibitor	18	10	Soft tissues, intra-abdominal	86	54	102	1	0	64
6	68/M	None	54	14	Soft tissues, epistaxis	94	87	218	4	2	76

Pt	Age/Sex	Underlying condition	Titer at treatment, BU/mL		Bleeding	Time to 50% increase in FVIII, d	Time to 50% decline in inhibitor, d	Time to nadir inhibitor, d	Nadir inhibitor titer (BU/mL)		Maximum FVIII, %
Pt	Age/Sex	Underlying condition	Human	Porcine	Bleeding	Time to 50% increase in FVIII, d	Time to 50% decline in inhibitor, d	Time to nadir inhibitor, d	Human	Porcine	Maximum FVIII, %
1	72/M	Chronic lymphocytic leukemia	26	3	Soft tissues	95	68	117	3	0	62
2	63/M	None	162	16	Soft tissues, hematuria	265	124	280	2	1	54
3	67/F	Scleroderma	24	2	Postoperative	105	79	145	2	1	82
4	59/F	Systemic lupus erythematosus	36	8	Skin, hemarthrosis	128	84	129	4	2	87
5	78/M	Colon cancer resected 2 years prior to inhibitor	18	10	Soft tissues, intra-abdominal	86	54	102	1	0	64
6	68/M	None	54	14	Soft tissues, epistaxis	94	87	218	4	2	76

Pt indicates patient; FVIII, factor VIII.